Alzheimer’s Disease - Pipeline Assessment and Market Forecasts to 2017 Alzheimer’s disease Therapeutics Market is Forecast to Show Slow Growth until 2017 GlobalData analysis shows that the global Alzheimer’s disease (AD) therapeutics market was valued at $7.1 billion in 2009. The market is expected to decline to $5.2 billion with a compound annual growth rate of -4% by the year 2017. The market structure is projected to change in the near future following the patent expiry of the leading drugs. The Aricept patent expires in November 2010, whilst Namenda’s patent is set to expire in April 2015. Due to the patent expiry of Aricept, the market is projected to decline with a CAGR of -16% by the year 2012. However, the 2012 onwards market is projected to grow with a CAGR of 0.5%`to reach above 5 billion by the year 2017. The pipeline of Alzheimer’s disease therapeutics is quite strong with disease modifying mechanisms. These products – if approved by 2017 – will alter the market scenario. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Alzheimer’s-Disease--PipelineAssessment-and-Market-Forecasts-to2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuti cals_and_Healthcare GlobalData finds that current competition is weak and the marketed products are unsuccessful in meeting the needs of patients, leaving behind a larger segment of unmet need. The market, therefore, continues to present opportunities for stronger pipeline candidates as the current drugs are mainly aimed at the relief of symptoms rather than meeting clinical end points. The current drugs are mostly acetylcholinesterase inhibitors and N methyl D aspartate antagonists. This underexploited market holds significant potential for any new entrants with disease modifying capabilities. Designing disease modifying drugs rather than drugs for providing symptomatic relief is one of the key challenges of this market and could provide a significant market opportunity for any company. GlobalData has found that more than 250 products are in different developmental stages of drug development. Bapinuezumab, Gammagard, Seroquel and Dimebon in Phase III and AL-108 (Phase II) and Rember (Phase II) are the key products currently in the pipeline. Bapineuzumab and Gammagard, with features such as innovative mechanisms of action (immunological) targeting patients with Alzheimer’s disease, remain the most keenly watched products in the pipeline. Among the tau inhibitors, Rember, which is currently in phase II clinical trials, is one of the most promising drugs. Although these drugs have great potential to become the future gold standards for the treatment of the disease, they are still several years away from commercialization. GlobalData, the industry analysis specialist, has released its new report, “Alzheimer’s Disease - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Alzheimer’s disease market. The report identifies the key trends shaping and driving the global Alzheimer’s disease market. The
report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Alzheimer’s disease sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Alzheimer’s-Disease--PipelineAssessment-and-Market-Forecasts-to2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuti cals_and_Healthcare Visit our report store: http://www.globaldata.com For more details contact: pressreleases@globaldata.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782